Posted by Michael Wonder on 02 Sep 2021
Novartis gets FDA fast track designation for LNA043 in knee osteoarthritis
2 September 2021 - Novartis AG on Thursday said the U.S. FDA granted fast track designation to LNA043 for the treatment for osteoarthritis of the knee.
The Swiss drug maker said it is developing LNA043 as a potential first in class disease-modifying treatment for osteoarthritis.
